Inventor · disambiguated record
Samuel Wadsworth
Also filed as: WADSWORTH SAMUEL · WADSWORTH SAMUEL C · WADSWORTH SAMUEL CHARLES
25 granted patents·17 pending applications·1,260 citations·filing 1993–2025
97Inventor score
Files withGENZYME CORP24ULTRAGENYX PHARMACEUTICAL INC7ATHENA NEUROSCIENCES INC2ORIORDAN CATHERINE1SCARIA ABRAHAM1
Top patents by PatentIndex Score
42 records- 0198US5720936ATransgenic mouse assay for compounds affecting amyloid protein processingATHENA NEUROSCIENCES INC·Filed 1994·Granted Feb 24, 1998·174 cites·6 claims
- 0296US5824544AAdenovirus vectors for gene therapyGENZYME CORP·Filed 1995·Granted Oct 20, 1998·261 cites·6 claims
- 0396US5811633ATransgenic mouse expressing APP770Filed 1995·Granted Sep 22, 1998·153 cites·6 claims
- 0494US5707618AAdenovirus vectors for gene therapyGENZYME CORP·Filed 1995·Granted Jan 13, 1998·206 cites·8 claims
- 0592US7928072B2Multimeric constructsGENZYME CORP·Filed 2007·Granted Apr 19, 2011·21 cites·35 claims
- 0692US6020191AAdenoviral vectors capable of facilitating increased persistence of transgene expressionGENZYME CORP·Filed 1997·Granted Feb 1, 2000·127 cites·3 claims
- 0791US6287857B1Nucleic acid delivery vehiclesGENZYME CORP·Filed 1999·Granted Sep 11, 2001·115 cites·2 claims
- 0889US10183983B2Nucleic acids encoding fusion proteins comprising PDGF and VEGF binding portions and methods of using thereofGENZYME CORP·Filed 2017·Granted Jan 22, 2019·7 cites·8 claims
- 0988US10920245B2Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersGENZYME CORP·Filed 2017·Granted Feb 16, 2021·3 cites·3 claims
- 1088US7615537B2Methods for treating blood coagulation disordersGENZYME CORP·Filed 2001·Granted Nov 10, 2009·19 cites·49 claims
- 1187US9637534B2Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereofGENZYME CORP·Filed 2014·Granted May 2, 2017·8 cites·10 claims
- 1287US7312324B2Regulatory elements for delivery to the liverGENZYME CORP·Filed 2002·Granted Dec 25, 2007·14 cites·11 claims
- 1387US6632670B1AAV vectors for gene therapyGENZYME CORP·Filed 1996·Granted Oct 14, 2003·119 cites·17 claims
- 1478US8658602B2Multimeric constructsSCARIA ABRAHAM·Filed 2011·Granted Feb 25, 2014·4 cites·28 claims
- 1577US9890394B2Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersORIORDAN CATHERINE·Filed 2009·Granted Feb 13, 2018·4 cites·11 claims
- 1676US2025283088A1Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2025·Application pending·0 cites
- 1774US10640771B2Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2014·Granted May 5, 2020·1 cites·16 claims
- 1873US6541245B1Adenoviral helper vectorsGENZYME CORP·Filed 2000·Granted Apr 1, 2003·5 cites·7 claims
- 1972US9815892B2Multimeric constructsGENZYME CORP·Filed 2014·Granted Nov 14, 2017·1 cites·5 claims
- 2072US2022064262A1Fusion proteins comprising pdgf and vegf binding portions and methods of using thereofGENZYME CORP·Filed 2021·Application pending·0 cites
- 2167US12344842B2Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2020·Granted Jul 1, 2025·0 cites·16 claims
- 2267US11084864B2Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereofGENZYME CORP·Filed 2018·Granted Aug 10, 2021·0 cites·21 claims
- 2365US12472268B2Gene therapy for treating propionic acidemiaULTRAGENYX PHARMACEUTICAL INC·Filed 2019·Granted Nov 18, 2025·0 cites·28 claims
- 2464US2022340883A1USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTUREGENZYME CORP·Filed 2022·Application pending·0 cites
- 2563US11299715B2Use of iNOS inhibitors to increase viral yield in cultureGENZYME CORP·Filed 2014·Granted Apr 12, 2022·0 cites·9 claims
- 2661US2011034539A1Methods for treating blood coagulation disordersWADSWORTH SAMUEL·Filed 2009·Application pending·0 cites
- 2760US2025333763A1Gene therapy constructs for treating wilson diseaseULTRAGENYX PHARMACEUTICAL INC·Filed 2025·Application pending·0 cites
- 2858US2018155417A1Multimeric constructsGENZYME CORP·Filed 2017·Application pending·0 cites
- 2957US2008070297A1Regulatory elements for delivery to the liverGENZYME CORP·Filed 2007·Application pending·0 cites
- 3056US12338450B2Gene therapy constructs for treating Wilson diseaseULTRAGENYX PHARMACEUTICAL INC·Filed 2020·Granted Jun 24, 2025·0 cites·18 claims
- 3156US2025019721A1Compositions and methods for treating a muscular dystrophyULTRAGENYX PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 3255US5604131AcDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regionsATHENA NEUROSCIENCES INC·Filed 1993·Granted Feb 18, 1997·15 cites·3 claims
- 3355US2023235353A1Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aavULTRAGENYX PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 3454US2023129893A1Gene therapy for treating propionic acidemiaULTRAGENYX PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 3551US2004105845A1AAV vectors for gene therapyFiled 2003·Application pending·0 cites
- 3648US2022017922A1Methods and compositions for treating glycogen storage diseasesULTRAGENYX PHARMACEUTICAL INC·Filed 2019·Application pending·0 cites
- 3747US2004143104A1Methods of treating diabetes and other blood sugar disordersFiled 2003·Application pending·0 cites
- 3845US2005107318A1Methods of treating diabetes and other blood sugar disordersFiled 2003·Application pending·0 cites
- 3945US2002045250A1Methods for purified AAV vector productionFiled 2001·Application pending·0 cites
- 4043US2004023389A1Adenoviral vectors having nucleic acids encoding immunomodulatory moleculesFiled 2002·Application pending·0 cites
- 4138US2004002468A1Methods of treating diabetes and other blood sugar disordersGENZYME CORP·Filed 2002·Application pending·0 cites
- 4237US6303371B1Method of purified rAAV vector production in non-human cell line transfected with cocksackie and adenovirus receptorGENZYME CORP·Filed 1999·Granted Oct 16, 2001·3 cites·14 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →